Zevra Therapeutics (NASDAQ:ZVRA – Get Free Report) and Sigyn Therapeutics (OTCMKTS:SIGY – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, earnings, valuation, analyst recommendations, risk, institutional ownership and dividends.
Insider and Institutional Ownership
35.0% of Zevra Therapeutics shares are owned by institutional investors. Comparatively, 10.0% of Sigyn Therapeutics shares are owned by institutional investors. 2.4% of Zevra Therapeutics shares are owned by company insiders. Comparatively, 78.5% of Sigyn Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Analyst Ratings
This is a summary of recent ratings and price targets for Zevra Therapeutics and Sigyn Therapeutics, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Zevra Therapeutics | 1 | 1 | 6 | 0 | 2.63 |
| Sigyn Therapeutics | 0 | 0 | 0 | 0 | 0.00 |
Volatility & Risk
Zevra Therapeutics has a beta of 1.08, meaning that its share price is 8% more volatile than the S&P 500. Comparatively, Sigyn Therapeutics has a beta of -0.72, meaning that its share price is 172% less volatile than the S&P 500.
Profitability
This table compares Zevra Therapeutics and Sigyn Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Zevra Therapeutics | 41.93% | -51.40% | -19.40% |
| Sigyn Therapeutics | N/A | N/A | -3,743.20% |
Valuation and Earnings
This table compares Zevra Therapeutics and Sigyn Therapeutics”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Zevra Therapeutics | $84.39 million | 5.98 | -$105.51 million | $0.47 | 19.09 |
| Sigyn Therapeutics | N/A | N/A | -$3.34 million | ($4.19) | -0.12 |
Sigyn Therapeutics has lower revenue, but higher earnings than Zevra Therapeutics. Sigyn Therapeutics is trading at a lower price-to-earnings ratio than Zevra Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
Zevra Therapeutics beats Sigyn Therapeutics on 10 of the 13 factors compared between the two stocks.
About Zevra Therapeutics
Zevra Therapeutics, Inc. discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 1/2 clinical trial for the treatment of vascular Ehlers Danlos syndrome. In addition, it offers AZSTARYS, a once-daily treatment for attention deficit hyperactivity disorder in patients aged six years and older; OLPRUVA to treat urea cycle disorders; and Arimoclomol for the treatment of niemann pick disease type C, an ultra-rare neurodegenerative lysosomal storage disorder. The company has collaboration and license agreement with Commave Therapeutics SA to develop, manufacture and commercialize the company’s product candidates containing SDX and d-methylphenidate; and license agreement with Acer and Relief Therapeutics, Inc. to develop and commercialize rights for OLPRUVA. The company was formerly known as KemPharm, Inc. and changed its name to Zevra Therapeutics, Inc. in February 2023. Zevra Therapeutics, Inc. was incorporated in 2006 and is headquartered in Celebration, Florida.
About Sigyn Therapeutics
Sigyn Therapeutics, Inc., a development-stage company, provides therapeutic solutions in the United States. Its lead product candidate is Sigyn Therapy, a broad-spectrum blood purification technology designed to treat pathogen-associated inflammatory disorders, including endotoxemia and inflammation in end-stage renal disease patients, sepsis, community acquired pneumonia, drug resistant bacterial infections, and emerging pandemic threats. The company is also involved in evaluating the Sigyn Therapy to address various therapeutic targets, including endotoxin; peptidoglycan and lipoteichoic acid; viral pathogens; hepatic toxins; and tumor necrosis factor alpha, interleukin-1 beta, and interleukin 6, which are pro-inflammatory cytokines. In addition, it develops ChemoPrep to enhance the tumor site delivery of chemotherapy; ChemoPure to reduce treatment toxicity and inhibit the spread of cancer metastasis; and ImmunePrep to enhance the potential efficacy of immunotherapeutic antibodies. Sigyn Therapeutics, Inc. was founded in 2019 and is headquartered in San Diego, California.
Receive News & Ratings for Zevra Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zevra Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
